We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




RF Ablation for Early-Stage Breast Cancer

By HospiMedica staff writers
Posted on 12 Dec 2001
A study has shown that heating breast tumors with radiofrequency (RF) ablation can kill the cancerous cells and may represent a less-invasive way of treating early-stage breast cancer. More...
The findings were reported in the December 2001 issue of Cancer.

Lumpectomy followed by a course of radiation has proven to be as effective for early-stage breast cancer as mastectomy. This has increased interest in finding an even less-invasive way of treating stage 1 disease. The researchers, from the G. Pascale National Tumor Institute in Naples (Italy), decided to determine whether the success in treating liver tumors with RF ablation could also produce good results in breast cancer patients.

The ablation procedure uses ultrasound images on a monitor to guide a thin metal needle through the patient's skin into the tumor. The needle opens to extend antenna-like probes in all directions. The RF energy passes through the probes into the tumor tissue, heating it hot enough to kill the tumor cells and a small rim of normal tissue, leaving a safety margin around the tumor. The researchers used the procedure on 20 patients with stage 1 disease and six women with stage II tumors 3 cm or smaller. After treatment, the tumors were surgically removed from all patients and tested to see if any cancer cells survived. The results showed that no cancerous cells survived in or around the tumor in 25 of the 26 patients. One patient's removed tumor showed some cancer cells still alive near the needle insertion site.

The results of any long-term follow-up are not yet known. Some doctors have concerns because the procedure requires general anesthesia and because the scar tissue formed by burned tissue may be less cosmetically appealing than that formed by a lumpectomy.

"This is an interesting new technique that might have a niche somewhere, but its current limitations make it hard to see any advantage in breast cancer treatment over other methods already in use,” said Dr. Jeanne Petrek, attending surgeon at Memorial Sloan Kettering Cancer Center (New York, NY, USA).

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.